Skip to content

KRAIG BIOCRAFT LABORATORIES, INC.: 10-Q filed 2026-05-14

What KRAIG BIOCRAFT LABORATORIES, INC. reported in its quarterly report filed 2026-05-14 (fiscal Q1 2026): 32 published measures, 70 facts as tagged in accession 0001493152-26-023130.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-14
Fiscal period
fiscal Q1 2026
Accession
0001493152-26-023130 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KRAIG BIOCRAFT LABORATORIES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-313,721,832USD
At 2025-12-312,565,540USD
At 2025-03-311,316,047USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-3110,783,506USD
At 2025-12-3110,564,498USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-31-7,061,674USD
At 2025-12-31-7,998,958USD
At 2025-03-31-8,547,798USD
At 2024-12-31-8,149,621USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-03-312,890,990USD
At 2025-12-311,790,236USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-942,720USD90
2025-01-01 to 2025-03-31-600,033USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-529,718USD90
2025-01-01 to 2025-03-31-434,499USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-03-3114,116USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,644,588USD90
2025-01-01 to 2025-03-31158,236USD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-14,116USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-57,651,792USD
At 2025-12-31-56,709,072USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,090,869,198shares90
2025-01-01 to 2025-03-311,041,458,063shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-311,090,869,198shares90
2025-01-01 to 2025-03-311,041,458,063shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD/shares90
2025-01-01 to 2025-03-310USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD/shares90
2025-01-01 to 2025-03-310USD/shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-03-3132,897USD
At 2025-12-3125,003USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-825,500USD90
2025-01-01 to 2025-03-31-580,492USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-313,010,459USD
At 2025-12-311,868,641USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-3110,677,075USD
At 2025-12-3110,445,245USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-31825,500USD90
2025-01-01 to 2025-03-31580,492USD90

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2026-03-3174,307USD
At 2025-12-3129,067USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-3166,701USD90
2025-01-01 to 2025-03-3123,876USD90

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-3112,670,302USD
At 2025-12-3112,434,886USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-03-31156,635USD
At 2025-12-31170,463USD
At 2025-10-01140,038USD
At 2024-09-2039,489USD
At 2024-01-3130,084USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-03-31158,036USD
At 2025-12-31171,162USD
At 2025-10-01140,038USD
At 2024-09-2039,489USD
At 2024-01-3130,084USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-03-31251,355USD
At 2025-12-31245,133USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-942,720USD90
2025-01-01 to 2025-03-31-600,033USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31495,566USD90
2025-01-01 to 2025-03-31308,851USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-01-01 to 2026-03-316,222USD90
2025-01-01 to 2025-03-315,683USD90

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-03-31148,433USD90
2025-01-01 to 2025-03-31140,348USD90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-117,220USD90
2025-01-01 to 2025-03-31-19,541USD90

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2026-01-01 to 2026-03-3128,346USD90
2025-01-01 to 2025-12-3147,583USD365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-3145,240USD90

Inspect the source

Entity
KRAIG BIOCRAFT LABORATORIES, INC. / CIK 0001413119
Captured
2026-09-20T08:02:08.774Z
SEC response SHA-256
920795b2181369f3ae04be68b2de22ae3d9ee7808a72922b976f9dc124464bc6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001413119.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))